ArticleThe American journal of pathology2016
Pre-Existing Mature Oligodendrocytes Do Not Contribute to Remyelination following Toxin-Induced Spinal Cord Demyelination.
Article in The American journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Beyond Histamine Blockade: Clemastine Fumarate as a Promoter of Myelin Regeneration, Inflammatory Regulation, and Neuroimmune Modulation in CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- A human-induced pluripotent stem cell-derived spheroid model to investigate myelin injury and repair.Nature neuroscience · 2026Article
- Myelin Repair as a Neuroprotective Strategy for Multiple Sclerosis: From Bench to Bedside.Medicina (Kaunas, Lithuania) · 2026Review
- Repair mechanisms of the central nervous system: From axon sprouting to remyelination.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Multiple sclerosis: what have we learned and can we still learn from electron microscopy.Cellular and molecular life sciences : CMLS · 2025Review
- Oligodendroglia and Myelin: Supporting the Connectome.Advances in neurobiology · 2025Review
- Myelin Repair as a Novel Mechanism for Ketamine's Sustained Antidepressant Effects.Current neuropharmacology · 2025Review
- Plasticity of Myelination.Advances in neurobiology · 2025Review
- The Role of Estrogen in Brain MicroRNAs Regulation.Advanced pharmaceutical bulletin · 2024Review
- Mechanisms of Transsynaptic Degeneration in the Aging Brain.Aging and disease · 2024Review
- A New Acquaintance of Oligodendrocyte Precursor Cells in the Central Nervous System.Neuroscience bulletin · 2024Review
- Review
- Remyelination in the Central Nervous System.Cold Spring Harbor perspectives in biology · 2024Review
- Extracellular vesicles released by microglia and macrophages carry endocannabinoids which foster oligodendrocyte differentiation.Frontiers in immunology · 2024Article
- Endogenous Sox8 is a critical factor for timely remyelination and oligodendroglial cell repletion in the cuprizone model.Scientific reports · 2023Article
- Understanding the Role of the Glial Scar through the Depletion of Glial Cells after Spinal Cord Injury.Cells · 2023Review
- Inflammation in multiple sclerosis: consequences for remyelination and disease progression.Nature reviews. Neurology · 2023Review
- Mature and Myelinating Oligodendrocytes Are Specifically Vulnerable to Mild Fluid Percussion Injury in Mice.Neurotrauma reports · 2023Article
- Oligodendroglial macroautophagy is essential for myelin sheath turnover to prevent neurodegeneration and death.Cell reports · 2022Article
- Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination.Inflammation and regeneration · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Remyelination is the regenerative response to demyelination. Although the oligodendrocyte progenitor is established as the major source of remyelinating cells, there is no conclusive evidence on whether mature, differentiated oligodendrocytes can also contribute to remyelination. Using two different inducible myelin-CreER mouse strains in which mature oligodendrocytes were prelabeled by the expression of membrane-bound Green fluorescent protein, we found that after focal spinal cord demyelination, the surrounding surviving labeled oligodendrocytes did not proliferate but remained at a consistent density. Furthermore, existing (prelabeled) oligodendrocytes showed no evidence of incorporation or migration into the lesioned area, or of process extension from the peripheral margins into the lesion. Thus, mature oligodendrocytes do not normally contribute to remyelination and are therefore not a promising target for regenerative therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.